drugset / Trial / NCT04815096
Imaging Immune Activation in COVID-19
Phase 2
Recruiting
80 enrolled
CellSight Technologies, Inc.
University of California, San Francisco · collab
NaSingle-groupOpen-labelBasic science
Summary
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \[18F\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.
Timeline
- Start
- 2021-04-15
- Primary completion
- 2027-10-01
- Completion
- 2028-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F-ARAG | Diagnostic / imaging agent | — | Intravenous |